COMMUNIQUÉS West-GlobeNewswire

Indegene Hosts Inaugural Strategic Advisory Board Meeting Chaired By Renowned Global Biopharma Leader Jill DeSimone
02/04/2024
PRINCETON, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, hosted its first Strategic Advisory Board (SAB) meeting recently in New Jersey, chaired by Jill [...]
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
02/04/2024
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, [...]
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
02/04/2024
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff [...]
Novo Nordisk A/S - share repurchase programme
02/04/2024
Bagsværd, Denmark, 2 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
02/04/2024
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) [...]
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02/04/2024
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles
02/04/2024
LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 366 owned and/or operated [...]
BioPorto A/S to Host Annual Earnings Webcast
02/04/2024
April 2, 2024 News release BioPorto A/S to Host Annual Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
02/04/2024
Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 [...]
Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023
02/04/2024
Amélioration notable de la visibilité sur les perspectives règlementaires et commerciales aux États-Unis depuis les derniers échanges avec la FDA. Attente d’une obtention de l’Autorisation d’Utilisation d’Urgence (EUA) [...]
Transactions in Connection with Share Buy-back Program
02/04/2024
Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
02/04/2024
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for [...]
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
02/04/2024
April 2, 2024 Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or [...]
ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System
02/04/2024
FDA clearance would allow the Company to market its breakthrough therapy to improve or restore hand and arm function after spinal cord injury in the US THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING [...]
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
02/04/2024
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173 [...]
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology
02/04/2024
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology Nantes, France, le 2 avril 2024, 7 heures 30 – OSE [...]
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02/04/2024
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated [...]
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
02/04/2024
Ipsen obtient les droits mondiaux exclusifs de développement et de commercialisation de STRO-003, un conjugué anticorps-petite molecule en voie de franchir les dernières étapes de développement préclinique. STRO-003 [...]
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
02/04/2024
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading [...]

Pages